Rituximab News and Research

RSS
Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
Vaccine-induced immune responses for SARS-CoV-2 in patients receiving anti-CD20 B-cell depleting therapies

Vaccine-induced immune responses for SARS-CoV-2 in patients receiving anti-CD20 B-cell depleting therapies

Results of high-impact clinical trials could affect kidney-related medical care

Results of high-impact clinical trials could affect kidney-related medical care

Ibrutinib plus standard chemotherapy effective in younger patients with diffuse large B-cell lymphoma

Ibrutinib plus standard chemotherapy effective in younger patients with diffuse large B-cell lymphoma

Immunocompromised patients using rituximab could benefit from third COVID-19 booster vaccine

Immunocompromised patients using rituximab could benefit from third COVID-19 booster vaccine

Study: Ultra-low rituximab dose maintains low disease activity for most RA patients

Study: Ultra-low rituximab dose maintains low disease activity for most RA patients

Study reassures the safety, immunogenicity of COVID-19 vaccines for patients with rheumatic diseases

Study reassures the safety, immunogenicity of COVID-19 vaccines for patients with rheumatic diseases

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

An investigation of three SARS-CoV-2 mRNA doses in multiple sclerosis vaccine non-responders

An investigation of three SARS-CoV-2 mRNA doses in multiple sclerosis vaccine non-responders

Factors contributing to a weak antibody response to the Pfizer COVID-19 vaccine

Factors contributing to a weak antibody response to the Pfizer COVID-19 vaccine

The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy

The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

Modified R-CODOX-M/IVAC regimen shows promise for treating sporadic Burkitt lymphoma

Modified R-CODOX-M/IVAC regimen shows promise for treating sporadic Burkitt lymphoma

Persistence of Anti-PF4 levels in VITT patients four months after AstraZeneca COVID-19 vaccine

Persistence of Anti-PF4 levels in VITT patients four months after AstraZeneca COVID-19 vaccine

Naive B cells could be useful for predicting vaccination response in immunocompromised

Naive B cells could be useful for predicting vaccination response in immunocompromised

Immunogenicity of mRNA vaccine against emerging strains of SARS-CoV-2 in immunocompromised patients

Immunogenicity of mRNA vaccine against emerging strains of SARS-CoV-2 in immunocompromised patients

Breakthrough SARS-CoV-2 infections in patients with systemic rheumatic diseases

Breakthrough SARS-CoV-2 infections in patients with systemic rheumatic diseases

Study shows impaired SARS-CoV-2 mRNA vaccine antibody response in individuals with chronic conditions

Study shows impaired SARS-CoV-2 mRNA vaccine antibody response in individuals with chronic conditions

Combination therapy improves outcomes for relapsed chronic lymphocytic leukemia

Combination therapy improves outcomes for relapsed chronic lymphocytic leukemia

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

Three new guidelines released for treatment and management of systemic vasculitis

Three new guidelines released for treatment and management of systemic vasculitis